Randomized trial shows OLR1's impact on tumor immunity in various cancers, suggesting important links to prognosis.
Key Points
This research investigates the role of OLR1 across multiple cancer types, focusing on its expression in relation to tumor immunity and clinical outcomes.
Analyzed pan-cancer multi-omics data from The Cancer Genome Atlas (TCGA) and public databases using R-based approaches.
Utilized single-cell RNA sequencing to assess cell-type-specific expression and communication.
Processed spatial transcriptomics datasets to explore OLR1's spatial distribution and co-localization with immune cells.
OLR1 showed upregulation in tumors like BLCA, BRCA, and CHOL, while downregulated in LUAD and LUSC, with prognostic implications for survival.
Significant negative correlations were observed between OLR1 expression and DNA methylation in various cancers.
Immune infiltration analysis indicated OLR1's strong correlation with immune cell types, especially macrophages and B cells.